Ethical concerns about non-active conditions in smoking cessation trials and methods to decrease such concerns

Drug and Alcohol Dependence

Volumn 100, Issue 3, 2009, Pages 187-193

  Hughes, John R ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Control groups; Ethics; Methods; Placebo; Smoking; Smoking cessation; Tobacco use cessation

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NORTRIPTYLINE;

ADD ON THERAPY; BEHAVIOR THERAPY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROL GROUP; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INFORMED CONSENT; MEDICAL LITERATURE; METHODOLOGY; NICOTINE REPLACEMENT THERAPY; PATIENT PARTICIPATION; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT FAILURE;

CLINICAL TRIALS AS TOPIC; CONTROL GROUPS; ETHICAL ANALYSIS; HUMANS; SMOKING; SMOKING CESSATION;

NICOTIANA TABACUM;

EID: 58149380532     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.10.020     Document Type: Review

References (53)

1. Appelbaum P.S., and Lidz C.W. Re-evaluating the therapeutic misconception: Response to Miller and Joffe. Kennedy Inst. Ethics J. 16 (2006) 367-373
2. Borkovec T.D., and Sibrava N.J. Problems with the use of placebo conditions in psychotherapy research, suggested alternatives, and some strategies for the pursuit of the placebo phenomenon. J. Clin. Psychol. 61 (2005) 805-818
3. Carpenter W., Appelbaum P., and Levine R. The declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in Schizophrenia. Am. J. Psychiatry 160 (2003) 356-362
4. Cokkinides V.E., Ward E., Jemel A., and Thun M.J. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am. J. Prev. Med. 28 (2005) 119-122
5. Ellenberg S.S., and Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2. Practical issues and specific cases. Ann. Int. Med. 133 (2000) 464-470
6. Emanuel E.J., and Miller F.G. The ethics of placebo-controlled trials-a middle ground. N. Engl. J. Med. 345 (2001) 915
7. Forman R.F., Bovasso G., Woody G., McNicholas L., Clark C., Royer-Malvestuto C., and Weinstein S. Staff beliefs about drug abuse clinical trials. J. Subst. Abuse TX 23 (2002) 55-60
8. Forster H.P., Emanuel E.J., and Grady C. The 2000 revision of the declaration of Helsinki: a step forward or more confusion?. Lancet 358 (2001) 1449-1453
9. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., and Reeves K.R. Varenicline, a a4B2 nicotinic acetylcholine receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation. JAMA 296 (2006) 47-55
10. Haggstram F.M., Chatkin J.M., Sussenbach-Vaz E., Cesari D.H., Fam C.F., and Fritscher C.C. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm. Pharmacol. Ther. 19 (2006) 205-209
11. Hall S.M., Humfleet G.L., Reus V.I., Munoz R.F., Hartz D.T., and Griffin R.M. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry 59 (2002) 930-936
12. Hrobjartsson A., and Gotzsche P.C. Is the placebo powerless? An analysis of clinical rials comparing placebo with no treatment. N. Engl. J. Med. 344 (2001) 1594-1602
13. Hrobjartsson, A., Gotzsche, P.C., 2007. Placebo interventions for all clinical conditions. The Cochrane Library, www.thecochranelibrary.com.
14. Hughes J.R. Motivating and helping smokers stop smoking. J. Gen. Int. Med. 18 (2003) 1053-1057
15. Hughes, J.R., Stead, L.F., Lancaster, T., 2007. Antidepressants for smoking cessation.
16. Huston P., and Peterson R. Withholding proven treatment in clinical research. N. Engl. J. Med. 345 (2001) 912-914
17. Irvin J.E., Hendricks P.S., and Brandon T.H. The increasing recalcitrance of smokers in clinical trials. II. Pharmacotherapy trials. Nicotine Tob. Res. 5 (2003) 27-35
18. Jarvis M.J., Raw M., Russell M.A., and Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br. Med. J. 285 (1982) 537-540
19. Jensen E.J., Schmidt E., Pedersen B., and Dahl R. Effect on smoking cessation of silver acetate, nicotine and ordinary chewing gum. Psychopharm 104 (1991) 470-474
20. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., and Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340 (1999) 685-691
21. Jorenby D., Hays J., Rigotti N., Azoulay S., Watsky E., Williams K., Billing C., Gong J., and Reeves K. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist vs. placebo or sustained-release bupropion for smoking cessation. JAMA 296 (2006) 56-63
22. Kleber H.D., Weiss R.D., Anton Jr. R.F., George T.P., Greenfield S.F., Kosten T.R., O'Brien C.P., Rounsaville B.J., Strain E.C., Ziedonis D.M., Hennessy G., and Connery H.S. Practice Guideline for the Treatment of Patients with Substance Use Disorders. second edition (2006), American Psychiatric Press, Washington, DC
23. Lancaster, T., Stead, L.F., 2005. Individual behavioural counselling for smoking cessation. The Cochrane Library, www.tthecochranelibrary.com.
24. Miller F.G., and Joffe S. Evaluating the therapeutic misconception. Kennedy Inst. Ethics J. 16 (2006) 353-366
25. Mooney M., White T., and Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind clinical trials. Addict. Behav. 29 (2004) 673-684
26. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E., Anziano R., and Reeves K. Smoking cessation with varenicline, a selective a4b2 nicotine receptor partial agonist. Arch. Int. Med. 166 (2006) 1561-1568
27. Nissen S., Nicholls S., Wolski K., Rodes-Cabau J., Cannon C., Deanfield J., Despres J., Kastelein J., Steinhubl S., Kapadia S., Yasin M., Ruzyllo W., Gaudin C., Job B., Hu B., Bhatt D., Lincoff A., and Tuzcu E. Effect of Rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. JAMA 299 (2008) 1547-1560
28. O'Leary K.D., and Brokovec T.D. Conceptual, methodological, and ethical problems of placebo groups in psychotherapy research. Am. Psychol. (1978) 821-830
29. Piaggio G., Elbourne D., Altman D., Pocock S., and Evans S. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 295 (2006) 1152-1160
30. Piper M.E., Federman E.B., McCarthy D.E., Bolt D.M., Smith S.S., Fiore M.C., and Baker T.B. Efficacy of bupropion alone and incombination with nicotine gum. Nicotine Tob. Res. 9 (2007) 947-954
31. Rose J.E., Behm F.M., and Westman E.C. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp. Clin. Psychopharm. 6 (1998) 331-343
32. Rothman K.J.M.K.B. The continuing unethical use of placebo controls. N. Engl. J. Med. 331 (1994) 394-398
33. Schulz K.F., and Grimes D.A. Multiplicity in randomised trials. II. subgroup and interim analyses. Lancet 365 (2005) 1657-1661
34. Shelton J.D. Ethical study design. Lancet 358 (2001) 839-840
35. Shiffman S., Di Marino M.E., and Sweeney C.T. Characteristics of selectors of nicotine replacement therapy. Tob. Control 14 (2005) 346-355
36. Shiffman S., Brockwell S.E., Pillitteri J.L., and Gitchell J.G. Use of smoking-cessation treatments in the United States. Am. J. Prev. Med. 34 (2008) 102-111
37. Silagy, C., Lancaster, T., Stead, L., Mant, D., Fowler, G., 2004. Nicotine replacement therapy for smoking cessation. The Cochrane Library, www.thecochranelibrary.com.
38. Spanier C.A., Shiffman S., Maurer A., Reynolds W., and Quick D. Rebound following failure to quit smoking: the effects of attributions and self-efficacy. Exp. Clin. Psychopharm. 4 (1996) 191-197
39. Spilker B. Guide To Clinical Trials (2000), Lippincott Williams & Wilkins, Philadephia, PA
40. Stead, L.F., Perera, R., Lancaster, T., 2006. Telephone counseling for smoking cessation. The Cochrane Library, www.thecochranelibrary.com.
41. Stead, L.F., Lancaster, T., 2005. Group behaviour therapy programmes for smoking cessation. The Cochrane Library, www.thecochranelibrary.com.
42. Temple R., and Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluationof new treatments. Part 1. Ethical and scientific issues. Ann. Int. Med. 133 (2000) 455-463
43. The Clinical Practice Guideline Treating Tobacco Use and Dependence, 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. Am. J. Prev. Med. 35 (2008) 158-176
44. Tollman S.M. What are the effects of the fifth revision of the declaration of Helsinki?. Br. Med. J. 323 (2001) 1417-1421
45. US Center for Disease Control. Tobacco use among adults-United States, 2005. MMWR 55 (2006) 1145
46. US Department of Health and Human Services, 1990. The Health Benefits of Smoking Cessation. A Report of the US Surgeon General. Office on Smoking & Health, Rockville, MD.
47. US Food and Drug Administration, 2001. Guidance for Industry E 10. Choice of Control Group and Related Issues in Clinical Trials.
48. Uyar M., Filiz A., Bayram N., Elbek O., Herken H., Topcu A., Dikensoy O., and Ekinci E. A randomized trial of smoking cessation. Saudi Med. J. 28 (2007) 922-926
49. Wagena E.J., Knipschild P.G., Huibers M.J.H., Wouters E.F.M., and van Schayck P. Effacacy of burpropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch. Int. Med. 165 (2005) 2286-2292
50. Weiss Roberts L., Lauriello J., Geppert C., and Keith S.J. Placebos and paradoxes in psychiatric research: an ethics perspective. Soc. Biol. Psychiatry 49 (2001) 887-893
51. West R. The clinical significance of 'small' effects of smoking cessation treatments. Addiction 102 (2007) 506-509
52. West, R., 2005. Smoking: prevalence, mortality and cessation in Great Britain, www.rjwest.co.uk/smokingcessationb.pdf.
53. West R., McNeill A., and Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 55 (2000) 987-999